

# Sarju Ganatra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7322512/publications.pdf>

Version: 2024-02-01

61  
papers

3,809  
citations

304743

22  
h-index

189892

50  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3487  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 98-104.	0.4	5
2	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
3	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
4	Oral anticoagulation therapies among Medicare beneficiaries: Utilization and costs. <i>Vascular Medicine</i> , 2022, 27, 490-492.	1.5	1
5	T-cell Immunotherapy and Cardiovascular Disease. <i>Heart Failure Clinics</i> , 2022, 18, 443-454.	2.1	2
6	Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement. <i>Current Cardiology Reports</i> , 2022, 24, 1117-1127.	2.9	6
7	Editorial commentary: Cardiovascular imaging in COVID-19: Focus on safety, value, and clinical relevance. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 17-19.	4.9	1
8	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
9	Management of Patients With Giant Cell Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1122-1134.	2.8	59
10	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	2.8	97
11	Cardiotoxicity Monitoring in Patients With Cancer: Focus on Safety and Clinical Relevance. <i>JCO Oncology Practice</i> , 2021, 17, 237-239.	2.9	2
12	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	4.0	85
13	B-PO04-140 TRENDS AND OUTCOMES OF ARRHYTHMIA IN CHRONIC LYMPHOCYTIC LEUKEMIA HOSPITALIZATIONS. <i>Heart Rhythm</i> , 2021, 18, S336-S337.	0.7	0
14	Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer. <i>Heart Rhythm</i> , 2021, 18, 1533-1538.	0.7	0
15	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>International Journal of Cardiology</i> , 2021, 323, 188-191.	1.7	7
16	Mycobacterium Chimaera Mimicking Sarcoidosis. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 14, 301.	1.0	6
17	Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. <i>Kidney360</i> , 2021, 2, 33-41.	2.1	23
18	Hypothyroidism and the Heart: Much More Than Meets the Eye. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 13, 261.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Angiotensin II Administration in Patients With COVID-19 Shock. <i>Critical Pathways in Cardiology</i> , 2021, 20, 100-102.	0.5	7
20	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. <i>Open Heart</i> , 2021, 8, e001849.	2.3	8
21	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.9	34
22	BLEOMYCIN PERICARDIAL SCLEROSIS: A SAFE AND EFFECTIVE THERAPY FOR MALIGNANT PERICARDIAL EFFUSION. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3319.	2.8	0
23	ANGIOEDEMA WITH SACUBITRIL/VALSARTAN: TRIAL-LEVEL META-ANALYSIS OF OVER 15,000 PATIENTS & REAL-WORLD EVIDENCE TO DATE. <i>Journal of the American College of Cardiology</i> , 2020, 75, 791.	2.8	0
24	Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Circulation</i> , 2020, 142, 1687-1690.	1.6	70
25	Risk and predictors of dyssynchrony cardiomyopathy in left bundle branch block with preserved left ventricular ejection fraction. <i>Clinical Cardiology</i> , 2020, 43, 1494-1500.	1.8	8
26	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	329.8	29
27	Lack of Association Between Left Ventricular Dyssynchrony and The Development of Cardiomyopathy in Patients with Left Bundle Branch Block and Initially Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, S29.	1.7	0
28	Acute Heart Failure and Atrial Fibrillation with Rapid Ventricular Response - Role of Gender and Alcohol in Suspected Tachycardia-induced Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2020, 26, S77.	1.7	0
29	How to Diagnose and Manage Radiation Cardiotoxicity. <i>JACC: CardioOncology</i> , 2020, 2, 655-660.	4.0	6
30	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 315-325.	4.9	44
31	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
32	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	2.2	212
33	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
34	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	2.8	179
35	The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 350-355.	4.0	92
36	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, , 1-10.	4.9	22

#	ARTICLE	IF	CITATIONS
37	Implementation of Cardio-Oncology Training for Cardiology Fellows. JACC: CardioOncology, 2020, 2, 795-799.	4.0	6
38	Incidence of Primary, Dilated Rather Than Tachycardia-Induced Cardiomyopathy among Patients Presenting with New Onset Atrial Arrhythmia and Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, S82.	1.7	0
39	Preparing the Cardiovascular Workforce to Care for Oncology Patients. Journal of the American College of Cardiology, 2019, 73, 2226-2235.	2.8	56
40	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 2019, 5, 1.	1.7	54
41	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
42	Cardiotoxicity of Immune Therapy. Cardiology Clinics, 2019, 37, 385-397.	2.2	54
43	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. Journal of the American College of Cardiology, 2019, 74, 3153-3163.	2.8	78
44	Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology, 2019, 5, 18.	1.7	87
45	Case-control study of heart rate abnormalities across the breast cancer survivorship continuum. Cancer Medicine, 2019, 8, 447-454.	2.8	4
46	Abstract 174: Healthcare Provider Compliance with the 2013 ACC/AHA Blood Cholesterol Guidelines for Statin Therapy for Diabetic Patients of Ages 40 to 75. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, .	2.2	0
47	Pharmacomechanical Therapy for Deep-Vein Thrombosis. New England Journal of Medicine, 2018, 378, 1752-1753.	27.0	2
48	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	2.8	997
49	Without Further Delay: Lyme Carditis. American Journal of Medicine, 2018, 131, 384-386.	1.5	7
50	Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1491-1500.	3.2	134
51	Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist, 2018, 23, 879-886.	3.7	207
52	Cardio-Oncology for GenNext. Journal of the American College of Cardiology, 2018, 71, 2977-2981.	2.8	20
53	Propafenone Induced 1:1 Atrial Flutter Conduction. Cardiovascular Pharmacology: Open Access, 2018, 07, .	0.1	0
54	Overuse of Cardiac Testing. American Family Physician, 2018, 98, 561-563.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Intracranial hemorrhage in a patient with subâ€massive pulmonary embolism treated with EkoSonic endovascular system directed thrombolysis. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 476-479.	1.7	6
56	CHALLENGES IN IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2308.	2.8	5
57	EXPANDING THE ROLE OF DEXRAZOXANE FOR CARDIOPROTECTION: USE IN A PATIENT WITH PRE-EXISTING SYSTOLIC DYSFUNCTION AND NO PRIOR ANTHRACYCLINE EXPOSURE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2389.	2.8	0
58	A Differing Opinion on Primary Percutaneous Coronary Intervention in Patients Who Have Had Cancer: Stent Choice in Onco-cardiology Revisited. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1315-1316.	3.0	5
59	A Dual-Snare Percutaneous Retrieval ofÂVenous Stent Embolization toÂtheÂRightÂHeart. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e111-e113.	2.9	6
60	Re-Evaluating the Safety of Drug-ElutingÂStents in Cancer Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2334-2337.	2.9	22
61	A rare form of imported infectious heart block. <i>Grand Rounds</i> , 2013, 13, 27-29.	0.2	0